“Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy” (2025) Farmeconomia. Health Economics and Therapeutic Pathways, 26(1). doi:10.7175/fe.v26i1.1574.